$1.51
-0.18 (-10.65%)
Labopharm, Inc. (DDSS)
CAPS Rating:
An international, specialty pharmaceutical company focused on improving existing drugs by incorporating its proprietary, advanced controlled-release technologies.

RSS Headlines
Fool UK
Recs
A nice Canadian biotech company with moderate near-term profit potential. The stock has been beaten way down in the past month because of a 2nd 'approvable' letter from the FDA regarding tramadol. But tramadol just gained approval in Canada, and I anticipate that they'll eventually get this through the FDA as well. When it does, you can expect an instant 300% profit. Meanwhile, the stock sits at a point too damn low for a company with DDSS's potential. Even while the market waits to see what the result of talks with the FDA are, I expect a healthy correction back into the $4.00 range. While the company remains partially under the radar, it was just raised from 'sell' to 'hold' by one of the few analysts.